TCL Archive Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial January 27, 2012
TCL Archive Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival April 25, 2014